The Oncosearch | Oncotarget

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer Research Paper

Bernardo Queralt, Elisabet CuyÃ s, Joaquim Bosch-Barrera, Anna Massaguer, Rafael de Llorens, BegoÃ±a Martin-Castillo, Joan Brunet, Ramon Salazar, Javier A. Menendez

Published Dec 13, 2016 · Vol. 7, No. 50 · pp. 82185-82199

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF^V600E targeted inhibition in a novel syngeneic murine glioma model Research Paper

Stefan Grossauer, Katharina Koeck, Nicole E. Murphy, Ian D. Meyers, Mathieu Daynac, Nathalene Truffaux, Albert Y. Truong, Theodore P. Nicolaides, Martin McMahon, Mitchel S. Berger, Joanna J. Phillips, David C. James, Claudia K. Petritsch

Published Oct 3, 2016 · Vol. 7, No. 46 · pp. 75839-75853

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model Research Paper

Kei Kawaguchi, Takashi Murakami, Bartosz Chmielowski, Kentaro Igarashi, Tasuku Kiyuna, Michiaki Unno, Scott D. Nelson, Tara A. Russell, Sarah M. Dry, Yunfeng Li, Fritz C. Eilber, Robert M. Hoffman

Published Sep 28, 2016 · Vol. 7, No. 44 · pp. 71737-71743

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations Research Paper

Mark Kerstjens, Emma M.C. Driessen, Merel Willekes, Sandra S. PinhanÃ§os, Pauline Schneider, Rob Pieters, Ronald W. Stam

Published Aug 31, 2016 · Vol. 8, No. 9 · pp. 14835-14846

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib Research Paper

Amir Noeparast, Erik Teugels, Philippe Giron, Gil Verschelden, Sylvia De Brakeleer, Lore Decoster, Jacques De GrÃ¨ve

Published Aug 26, 2016 · Vol. 8, No. 36 · pp. 60094-60108

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers Research Paper

Giulia Bon, Rossella Loria, Carla Azzurra Amoreo, Alessandra Verdina, Isabella Sperduti, Arianna Mastrofrancesco, Silvia Soddu, Maria Grazia Diodoro, Marcella Mottolese, Matilde Todaro, Giorgio Stassi, Michele Milella, Ruggero De Maria, Rita Falcioni

Published Aug 19, 2016 · Vol. 8, No. 65 · pp. 108463-108479

Fatal gastrointestinal toxicity with ipilimumab after BRAF/ MEK inhibitor combination in a melanoma patient achieving pathological complete response Research Paper

Maria Gonzalez-Cao, Aram Boada, Cristina TeixidÃ³, MarÃa Teresa Fernandez- Figueras, Clara Mayo, Francesc Tresserra, Jean Bustamante, Santiago Viteri, Enrique Puertas, Mariacarmela Santarpia, Aldo Riso, Feliciano Barron, Niki Karachaliou, Rafael Rosell

Published Jul 18, 2016 · Vol. 7, No. 35 · pp. 56619-56627

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma Research Paper

Giuliana Cavalloni, Caterina Peraldo-Neia, Chiara Varamo, Giovanna Chiorino, Francesco Sassi, Massimo Aglietta, Francesco Leone

Published Jul 13, 2016 · Vol. 7, No. 32 · pp. 52354-52363

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models Research Paper

Michael S. Lee, Timothy L. Helms, Ningping Feng, Jason Gay, Qing Edward Chang, Feng Tian, Ji Y. Wu, Carlo Toniatti, Timothy P. Heffernan, Garth Powis, Lawrence N. Kwong, Scott Kopetz

Published May 4, 2016 · Vol. 7, No. 26 · pp. 39595-39608

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA⁺ oral cancers Priority Research Paper

Kosuke Yamaguchi, Ramiro Iglesias-BartolomÃ©, Zhiyong Wang, Juan Luis Callejas-Valera, Panomwat Amornphimoltham, Alfredo A. Molinolo, Ezra E. Cohen, Joseph A. Califano, Scott M. Lippman, Ji Luo, J. Silvio Gutkind

Published Feb 13, 2016 · Vol. 7, No. 10 · pp. 10696-10709

Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts Research Paper

Peng Hu, Da-xiong Han, Run-sheng Ruan, Li-Mou Zheng, Shiu-Huey Chou, Chi-Meng Tzeng

Published Feb 2, 2016 · Vol. 7, No. 24 · pp. 35741-35752

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M^high melanoma cell populations Research Paper

Mariusz L. Hartman, Beata Talar, Malgorzata Sztiller-Sikorska, Dariusz Nejc, Malgorzata Czyz

Published Jan 27, 2016 · Vol. 7, No. 8 · pp. 9026-9040

Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling Research Paper

Chia-Wen Hsu, Ruili Huang, Thai Khuc, David Shou, Joshua Bullock, Suzanne Grooby, Sue Griffin, Chaozhong Zou, Annette Little, Holly Astley, Menghang Xia

Published Jan 23, 2016 · Vol. 7, No. 7 · pp. 8172-8183

Overexpression of Mcl-1 confers resistance to BRAF^V600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma Research Paper

Neel M. Fofaria, Dennie T. Frederick, Ryan J. Sullivan, Keith T. Flaherty, Sanjay K. Srivastava

Published Oct 14, 2015 · Vol. 6, No. 38 · pp. 40535-40556

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma Research Paper

Elin S. Gray, Helen Rizos, Anna L. Reid, Suzanah C. Boyd, Michelle R. Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny H.J. Lee, Richard A. Scolyer, Kelvin Siew, Chris Lomma, Adam Cooper, Muhammad A. Khattak, Tarek M. Meniawy, Georgina V. Long, Matteo S. Carlino, Michael Millward, Melanie Ziman

Published Sep 22, 2015 · Vol. 6, No. 39 · pp. 42008-42018

IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma Research Paper

Amy L. Myers, Lin Lin, Derek J. Nancarrow, Zhuwen Wang, Daysha Ferrer-Torres, Dafydd G. Thomas, Mark B. Orringer, Jules Lin, Rishindra M. Reddy, David G. Beer, Andrew C. Chang

Published Jul 17, 2015 · Vol. 6, No. 28 · pp. 25897-25916

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma Research Paper

Katherine E. Hutchinson, Douglas B. Johnson, Adam S. Johnson, Violeta Sanchez, Maria Kuba, Pengcheng Lu, Xi Chen, Mark C. Kelley, Qingguo Wang, Zhongming Zhao, Mark Kris, Michael F. Berger, Jeffrey A. Sosman, William Pao

Published Jun 13, 2015 · Vol. 6, No. 26 · pp. 22348-22360

Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells Research Paper

Chengguang Zhao, Hui Xiao, Xiaojuan Wu, Chenglong Li, Guang Liang, Shulin Yang, Jiayuh Lin

Published May 4, 2015 · Vol. 6, No. 16 · pp. 14472-14487

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter Research Paper

Jian-Ge Qiu, Yao-Jun Zhang, Yong Li, Jin-Ming Zhao, Wen-Ji Zhang, Qi-Wei Jiang, Xiao-Long Mei, You-Qiu Xue, Wu-Ming Qin, Yang Yang, Di-Wei Zheng, Yao Chen, Meng-Ning Wei, Zhi Shi

Published Apr 14, 2015 · Vol. 6, No. 17 · pp. 15494-15509

Epithelial to mesenchymal transition is associated with rapamycin resistance Research Paper

Ashley M. Holder, Argun Akcakanat, Farrell Adkins, Kurt Evans, Huiqin Chen, Caimiao Wei, Denai R. Milton, Yisheng Li, Kim-Anh Do, Filip Janku, Funda Meric-Bernstam

Published Apr 13, 2015 · Vol. 6, No. 23 · pp. 19500-19513

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer Research Paper

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF^V600E targeted inhibition in a novel syngeneic murine glioma model Research Paper

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model Research Paper

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations Research Paper

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib Research Paper

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers Research Paper

Fatal gastrointestinal toxicity with ipilimumab after BRAF/ MEK inhibitor combination in a melanoma patient achieving pathological complete response Research Paper

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma Research Paper

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models Research Paper

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA⁺ oral cancers Priority Research Paper

Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts Research Paper

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M^high melanoma cell populations Research Paper

Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling Research Paper

Overexpression of Mcl-1 confers resistance to BRAF^V600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma Research Paper

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma Research Paper

IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma Research Paper

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma Research Paper

Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells Research Paper

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter Research Paper

Epithelial to mesenchymal transition is associated with rapamycin resistance Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer Research Paper

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model Research Paper

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model Research Paper

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations Research Paper

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib Research Paper

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers Research Paper

Fatal gastrointestinal toxicity with ipilimumab after BRAF/ MEK inhibitor combination in a melanoma patient achieving pathological complete response Research Paper

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma Research Paper

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models Research Paper

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers Priority Research Paper

Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts Research Paper

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations Research Paper

Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling Research Paper

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma Research Paper

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma Research Paper

IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma Research Paper

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma Research Paper

Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells Research Paper

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter Research Paper

Epithelial to mesenchymal transition is associated with rapamycin resistance Research Paper

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF^V600E targeted inhibition in a novel syngeneic murine glioma model Research Paper

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA⁺ oral cancers Priority Research Paper

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M^high melanoma cell populations Research Paper

Overexpression of Mcl-1 confers resistance to BRAF^V600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma Research Paper